Bioatla's jay m. short, ph.d.

San diego, oct. 12, 2023 (globe newswire) -- bioatla, inc. (nasdaq: bcab), a global clinical-stage biotechnology company focused on the development of conditionally active biologic (cab) antibody therapeutics for the treatment of solid tumors, today announced that jay m. short, ph.d.
BCAB Ratings Summary
BCAB Quant Ranking